XTuit Pharmaceuticals move to appoint biotech veteran as CEO
XTuit Pharmaceuticals has revealed the appointment of Deborah Dunshire as its new President and CEO. XTuit Pharmaceuticals is a biotech company that develops novel therapeutics particularly focusing on disease-promoting microenvironments in fibrotic diseases and cancer. Dunshire arrives at the biotech having had plenty of experience within the pharmaceutical industry, with a number of leading roles within larger companies in the industry.
She joins with something of a point to prove, however, as her last position as CEO ended with FORUM Pharmaceuticals closing as a business. It had relied on trials for a candidate in Alzheimer’s disease and schizophrenia – but both fell short of the mark leading to the company shutting up shop.
Prior to this position, Dunshire had enjoyed a strong showing managing the takeover of Millennium Pharmaceuticals by Takeda. She also held numerous roles with Novartis, including Vice President and Senior VP of North America Oncology.
“I am delighted to join XTuit and its esteemed scientific founders, experienced investors, and the outstanding scientific team at the company. We are at an exciting stage with strong momentum to rapidly advance the company’s novel therapies which target master regulators in the microenvironment to address multiple disease pathways,” said Deborah Dunsire on her appointment. “The microenvironment remains an unaddressed therapeutic frontier. There is an increasing recognition that the microenvironment plays a central role in fibrosis and cancer, and new insights have emerged to guide our therapeutic approach to targeting the microenvironment to address challenging diseases. I believe XTuit has a rare opportunity to leverage its leadership in this field to develop novel therapies with the potential to reverse fibrosis and transform outcomes in cancer.”
“We welcome Deborah’s deep experience and strategic business acumen to help build our vision and future for XTuit,” said Alan Crane, partner at Polaris Partners and Chairman of the Board of XTuit. “Deborah’s exceptional track record of leadership and oncology expertise as well as a strong vision for building companies will serve XTuit exceptionally well as we embark on the next stage of transforming leading-edge science into important new medicines.”